India to Malta: Acetylsalicylic Export Trade Route

To import acetylsalicylic acid formulations into Malta, a Marketing Authorisation (MA) is mandatory. Applicants can pursue this through several procedures:

• National Procedure: For products intended solely for the Maltese market.

• Mutual Recognition Procedure (MRP): For products already authorised in another EU/EEA Member State.

• Decentralised Procedure (DCP): For simultaneous applications in multiple EU/EEA countries.

All applications must be submitted electronically via the Common European Submission Portal (CESP) in the electronic Common Technical Document (eCTD) format. Paper submissions are no longer accepted as of January 2022. Applicants must register their organisation with CESP to obtain login credentials. Detailed guidelines on dossier submission are provided in the MMA's GL-LI04 document. (medicinesauthority.gov.mt)

The MMA requires that all manufacturing sites involved in the production of the medicinal product comply with Good Manufacturing Practice (GMP) standards. This compliance must be confirmed by an inspectorate from the European Economic Area (EEA) or from a country with a valid mutual recognition agreement with the EU. The confirmation must specifically pertain to the site(s) manufacturing the bulk finished product and be based on a GMP inspection. (ema.europa.eu)

Indian manufacturers exporting acetylsalicylic acid formulations to Malta must adhere to EU GMP standards. Compliance is typically verified through inspections conducted by EEA authorities or those from countries with mutual recognition agreements with the EU. The EMA maintains a database of GMP-compliant manufacturing sites; however, specific details about individual Indian facilities are not publicly disclosed.

As of March 2026, there have been no publicly reported EMA regulatory actions against Indian pharmaceutical companies supplying acetylsalicylic acid formulations to Malta. Manufacturers are advised to stay updated on regulatory requirements and ensure continuous compliance with GMP standards to maintain market access.

In November 2025, the MMA revised its guidelines (GL-LI04 Revision 09) to mandate that all Power of Attorney (POA) documents submitted with applications must clearly state a validity period, with a maximum allowable duration of three years from the date of issue. Applications with expired or missing POA validity are not accepted. (medicinesauthority.gov.mt)

Additionally, the EMA is transitioning to a web-based electronic Application Form (eAF) via the Product Lifecycle Management (PLM) Portal, replacing older PDF forms. This new system offers smart data entry, real-time validation, and generates both PDF and XML outputs. It is expected to become mandatory for all procedures in the near future. (medicinesauthority.gov.mt)

These developments aim to streamline the application process and enhance regulatory compliance for pharmaceutical imports into Malta.

As of 2025, Malta's pharmaceutical market has been experiencing steady growth, driven by factors such as an aging population, increased healthcare spending, and a high prevalence of cardiovascular diseases, for which Acetylsalicylic acid formulations are commonly prescribed. While specific data on the market size for Acetylsalicylic acid formulations in Malta is limited, the country's reliance on imports for pharmaceutical products is significant. Domestic manufacturing of such formulations is minimal, necessitating substantial imports to meet local demand.

Malta, as a member of the European Union, imposes a Value Added Tax (VAT) of up to 18% on imported goods, including pharmaceutical products. However, finished pharmaceutical formulations containing Acetylsalicylic acid are exempt from import duties under the Most-Favored-Nation (MFN) status. There are no specific Free Trade Agreements (FTAs) between India and Malta that further affect pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on these products.

India is a major supplier of finished pharmaceutical formulations containing Acetylsalicylic acid to Malta, accounting for approximately 23.6% of India's total exports of such formulations, valued at $1.0 million USD across 59 shipments. Other significant suppliers to Malta include European Union manufacturers, who benefit from proximity and established trade relationships. While specific data on India's share of Malta's total Acetylsalicylic acid imports is not readily available, India's competitive pricing and manufacturing capabilities position it as a key player in Malta's pharmaceutical import market.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines as of 2024. This extensive manufacturing capability includes a significant output of finished dosage forms containing acetylsalicylic acid, such as tablets and capsules. The country's cost-effective production processes, driven by economies of scale and a competitive labor market, enable the delivery of high-quality acetylsalicylic formulations at affordable prices. India's pharmaceutical sector is supported by a robust regulatory framework, with over 670 USFDA-approved manufacturing facilities as of 2023, ensuring compliance with international quality standards.

When comparing acetylsalicylic formulations from India, China, and the European Union, several factors emerge:

• Cost: Indian manufacturers offer acetylsalicylic formulations at competitive prices due to efficient production methods and lower operational costs. Chinese producers also provide cost-effective options; however, concerns about quality and regulatory compliance have been noted. European manufacturers, while adhering to stringent quality standards, typically have higher production costs, resulting in more expensive formulations.

• Quality Perception: India's pharmaceutical industry is recognized for producing high-quality generic medicines, with numerous facilities meeting international regulatory standards. China has faced scrutiny over quality issues, leading to a perception of inconsistency. The EU maintains a strong reputation for quality, supported by rigorous regulatory oversight.

• Regulatory Acceptance in Malta: Malta, as an EU member state, requires pharmaceutical imports to comply with EU regulations. Indian manufacturers with EU GMP certifications are well-positioned to meet these requirements, facilitating smoother market entry.

• Supply Reliability Track Record: Indian pharmaceutical companies have established a reliable supply chain, consistently meeting global demand for generic medicines. While China has improved its supply capabilities, occasional disruptions have raised concerns. EU manufacturers are known for dependable supply but may face capacity constraints due to higher production costs.

The India-Malta supply chain for acetylsalicylic formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging facilities. Indian manufacturers have demonstrated resilience, maintaining consistent supply even during global disruptions. Compliance with international regulatory standards, including EU GMP, ensures product quality and safety. Leading Indian pharmaceutical companies continue to invest in expanding their production capacities to meet growing global demand.

For Maltese buyers sourcing acetylsalicylic formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a steady supply of formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, such as letters of credit or advance payments, to build trust and facilitate smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including audits and quality assessments, to ensure suppliers meet EU regulatory standards and possess necessary certifications.

• Regulatory Compliance: Verify that selected suppliers have EU GMP certification and a history of compliance with international quality standards to ensure seamless market entry into Malta.

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a minimum of 3-5 days on-site, depending on the facility's size and complexity.
• Estimated costs include auditor fees, travel, accommodation, and daily allowances, totaling approximately €10,000 to €15,000 per audit.

By adhering to this comprehensive approach, Malta-based companies can ensure the selection of reliable Indian suppliers for acetylsalicylic acid formulations, thereby safeguarding product quality and regulatory compliance.